Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis. (2nd October 2021)

• Record Type: Journal Article
• Authors: Olsson, Malin; Hellman, Urban; Wixner, Jonas; Anan, Intissar
• Is Part Of: Amyloid. Volume 28:Number 4(2021)
• Page Start: 234
• Page End: 242
• Publication Date: 2021-10-02
• Subjects: Amyloidosis -- transthyretin -- metabolomics -- mass spectrometry -- biomarker -- hereditary; Amyloidosis -- Periodicals; 616.3995
• DOI: 10.1080/13506129.2021.1958775
• Languages: English
• ISSNs: 1350-6129

Abstract

Abstract: Untargeted metabolomics is a well-established technique and a powerful tool to find potential plasma biomarkers for early diagnosing hereditary transthyretin amyloidosis. Hereditary transthyretin amyloidosis (ATTRv) is a disabling and fatal disease with different clinical features such as polyneuropathy, cardiomyopathy, different gastrointestinal symptoms and renal failure. Plasma specimens collected from 27 patients with ATTRv (ATTRV30M), 26 asymptomatic TTR V30M carriers and 26 control individuals were subjected to gas chromatography (GC)- and liquid chromatography (LC)-mass spectrometry (MS)-based metabolomics analysis. Partial least squares discriminant and univariate analysis was used to analyse the data. The models constructed by Partial least squares-discriminant analysis (PLS-DA) could clearly discriminate ATTRV30M patients from controls and asymptomatic TTR V30M carriers. In total, 24 plasma metabolites (VIP > 1.0 and p < .05) were significantly altered in ATTRV30M patient group (6 increased and 18 decreased). Eleven of these distinguished the ATTRV30M group from both controls and TTR V30M carriers. Plasma metabolomics analysis revealed marked changes in several pathways in patients with ATTRV30M amyloidosis. Statistical analysis identified a panel of biomarkers that could effectively separate controls/ TTR V30M carriers from ATTRV30M patients. These biomarkers can potentially be used to diagnose patients at an early stage of the disease.